1. Li T, Li J, Chen Z, et al. (2022): Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. J Control Release 352: 338-370.
2.
Lv K, Cao X, Wang R, et al. (2022): Neuroplasticity of glioma patients: Brain structure and topological network. Front Neurol 13: 871613.
3.
Jiang T, Nam DH, Ram Z, et al. (2021): Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett 499: 60-72.
4.
Zhu H, Hu X, Feng S, et al. (2022): Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients. Front Immunol 13: 946692.
5.
Cordier D, Krolicki L, Morgenstern A, et al. (2016): Targeted radiolabeled compounds in glioma therapy. Semin Nucl Med 46: 243-249.
6.
Park J, Hsueh PC, Li Z, et al. (2023): Microenvironment-driven metabolic adaptations guiding CD8(+) T cell anti-tumor immunity. Immunity 56: 32-42.
7.
Locy H, de Mey S, de Mey W, et al. (2018): Immunomodulation of the tumor microenvironment: Turn foe into friend. Front Immunol 9: 2909.
8.
Marabelle A, Kohrt H, Caux C, et al. (2014): Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 20: 1747-1756.
9.
Stanley ER, Chitu V (2014): CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol 6: a021857.
10.
Chitu V, Biundo F, Stanley ER (2021): Colony stimulating factors in the nervous system. Semin Immunol 54: 101511.
11.
Singhal A, Subramanian M (2019): Colony stimulating factors (CSFs): Complex roles in atherosclerosis. Cytokine 122: 154190.
12.
He K, Liu X, Hoffman RD, et al. (2022): G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors. FEBS Open Bio 12: 1268-1285.
13.
Aliper AM, Frieden-Korovkina VP, Buzdin A, et al. (2014): A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med 3: 737-746.
14.
Zhu Y, Knolhoff BL, Meyer MA, et al. (2014): CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74: 5057-5069.
15.
Karagiannidis I, Salataj E, Said Abu Egal E, et al. (2021): G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine 142: 155479.
16.
Miyoshi J, Zhu Z, Luo A, et al. (2022): A microRNA-based liquid biopsy signature for the early detection of esophageal squamous cell carcinoma: a retrospective, prospective and multicenter study. Mol Cancer 21: 44.
17.
Dwivedi P, Greis KD (2017): Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol 46: 9-20.
18.
Dong F, Brynes RK, Tidow N, et al. (1995): Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 333: 487-493.
19.
Germeshausen M, Ballmaier M, Welte K (2007): Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 109: 93-99.
20.
Fleischman AG, Maxson JE, Luty SB, et al. (2013): The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 122: 3628-3631.
21.
Pardanani A, Lasho TL, Laborde RR, et al. (2013): CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27: 1870-1873.
22.
Karagiannidis I, de Santana Van Vilet E, Said Abu Egal E, et al. (2020): G-CSF and G-CSFR induce a pro-tumorigenic macrophage phenotype to promote colon and pancreas tumor growth. Cancers (Basel) 12: 2868.
23.
Karagiannidis I, Jerman SJ, Jacenik D, et al. (2020): G-CSF and G-CSFR modulate CD4 and CD8 T cell responses to promote colon tumor growth and are potential therapeutic targets. Front Immunol 11: 1885.
24.
Ceccarelli M, Barthel FP, Malta TM, et al. (2016): Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164: 550-563.
25.
He Y, Jiang Z, Chen C, et al. (2018): Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res 37: 327.
26.
Yoshihara K, Shahmoradgoli M, Martinez E, et al. (2013): Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4: 2612.
27.
Newman AM, Liu CL, Green MR, et al. (2015): Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12: 453-457.
28.
Charoentong P, Finotello F, Angelova M, et al. (2017): Pan-cancer immunogenomic analyses reveal genotype- immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18: 248-262.
29.
Auslander N, Zhang G, Lee JS, et al. (2018): Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med 24: 1545-1549.
30.
Sun D, Wang J, Han Y, et al. (2021): TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res 49: D1420-D1430.
31.
Jiang Y, Ji Q, Long X, et al. (2022): CLCF1 is a novel potential immune-related target with predictive value for prognosis and immunotherapy response in glioma. Front Immunol 13: 810832.
32.
Jiang P, Gu S, Pan D, et al. (2018): Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24: 1550-1558.
33.
Cahill D, Turcan S (2018): Origin of gliomas. Semin Neurol 38: 5-10.
34.
Reni M, Mazza E, Zanon S, et al. (2017): Central nervous system gliomas. Crit Rev Oncol Hematol 113: 213-234.
35.
Davis ME (2018): Epidemiology and overview of gliomas. Semin Oncol Nurs 34: 420-429.
36.
Filbin MG, Suva ML (2016): Gliomas genomics and epigenomics: Arriving at the start and knowing it for the first time. Annu Rev Pathol 11: 497-521.
37.
Masliantsev K, Karayan-Tapon L, Guichet PO (2021): Hippo signaling pathway in gliomas. Cells 10: 184.
38.
Ferris SP, Hofmann JW, Solomon DA, et al. (2017): Characterization of gliomas: from morphology to molecules. Virchows Arch 471: 257-269.
39.
Wang J, Xiao Z, Li P, et al. (2023): PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B. Oncogene 42: 1088-1100.
40.
Fang R, Chen X, Zhang S, et al. (2021): EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun 12: 177.
41.
Jakubzick CV, Randolph GJ, Henson PM (2017): Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol 17: 349-362.
42.
Hettinger J, Richards DM, Hansson J, et al. (2013): Origin of monocytes and macrophages in a committed progenitor. Nat Immunol 14: 821-830.
43.
Haringman JJ, Gerlag DM, Zwinderman AH, et al. (2005): Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 834-838.
44.
Coillard A, Segura E (2019): In vivo differentiation of human monocytes. Front Immunol 10: 1907.
45.
Sheu KM, Hoffmann A (2022): Functional hallmarks of healthy macrophage responses: Their regulatory basis and disease relevance. Ann Rev Immunol 40: 295-321.
46.
Anderson NR, Minutolo NG, Gill S, et al. (2021): Macrophage-based approaches for cancer immunotherapy. Cancer Res 81: 1201-1208.
47.
Cassetta L, Pollard JW (2018): Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov 17: 887-904.
48.
Xu Y, Wang X, Liu L, et al. (2022): Role of macrophages in tumor progression and therapy (Review). Int J Oncol 60: 57.
49.
Zheng Y, Graeber MB (2022): Microglia and brain macrophages as drivers of glioma progression. Int J Mol Sci 23: 15612.
50.
Wei J, Chen P, Gupta P, et al. (2020): Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol 22: 180-194.
51.
Khan F, Lin Y, Ali H, et al. (2024): Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression. Nat Commun 15: 1987.
52.
Ni X, Wu W, Sun X, et al. (2022): Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv 8: eabl5165.
53.
Chen DS, Mellman I (2017): Elements of cancer immunity and the cancer-immune set point. Nature 541: 321-330.
54.
He W, Zhang H, Han F, et al. (2017): CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77: 6375-6388.
55.
Kim W, Chu TH, Nienhuser H, et al. (2021): PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice. Gastroenterology 160: 781-796.
56.
Liu JN, Kong XS, Huang T, et al. (2020): Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: A pan-cancer study. Front Immunol 11: 2048.
57.
Ausejo-Mauleon I, Labiano S, de la Nava D, et al. (2023): TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell 41: 1911-1926.e8.
58.
Arrieta VA, Dmello C, McGrail DJ, et al. (2023): Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest 133: e163447.
59.
Hung AL, Maxwell R, Theodros D, et al. (2018): TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 7: e1466769.
60.
Zhu Z, Zhang H, Chen B, et al. (2020): PD-L1-mediated immunosuppression in glioblastoma is associated with the infiltration and M2-polarization of tumor-associated macrophages. Front Immunol 11: 588552.
61.
Rao G, Latha K, Ott M, et al. (2020): Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells. Clin Cancer Res 26: 4699-4712.
